ATE285226T1 - Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs - Google Patents

Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs

Info

Publication number
ATE285226T1
ATE285226T1 AT98938469T AT98938469T ATE285226T1 AT E285226 T1 ATE285226 T1 AT E285226T1 AT 98938469 T AT98938469 T AT 98938469T AT 98938469 T AT98938469 T AT 98938469T AT E285226 T1 ATE285226 T1 AT E285226T1
Authority
AT
Austria
Prior art keywords
stomach
dosage form
active agent
active ingredient
polymer matrix
Prior art date
Application number
AT98938469T
Other languages
English (en)
Inventor
Liang C Dong
David E Edgren
Phyllis I Gardner
Francisco Jao
Felix Theeuwes
Jason Wan
Patrick S-L Wong
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE285226T1 publication Critical patent/ATE285226T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98938469T 1997-08-11 1998-08-10 Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs ATE285226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5547597P 1997-08-11 1997-08-11
PCT/US1998/016597 WO1999007342A1 (en) 1997-08-11 1998-08-10 Prolonged release active agent dosage form adapted for gastric retention

Publications (1)

Publication Number Publication Date
ATE285226T1 true ATE285226T1 (de) 2005-01-15

Family

ID=21998085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98938469T ATE285226T1 (de) 1997-08-11 1998-08-10 Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs

Country Status (9)

Country Link
US (2) US6120803A (de)
EP (1) EP1003476B1 (de)
JP (1) JP2001527023A (de)
AT (1) ATE285226T1 (de)
AU (1) AU8699298A (de)
DE (1) DE69828289T2 (de)
ES (1) ES2234139T3 (de)
PT (1) PT1003476E (de)
WO (1) WO1999007342A1 (de)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
ATE238773T1 (de) * 1997-08-26 2003-05-15 Aventis Pharma Inc Arzneimittel für die kombination piperidinoalkanol-dekongestivum
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
BR9908911A (pt) * 1998-03-19 2001-10-02 Bristol Myers Squibb Co Sistema bifásico e processo de distribuição por liberação controlada de substâncias farmacêuticas de alta solubilidade
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
EP1469009A2 (de) 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Zusammensetzungen und Verfahren für nicht-parenterale Verabreichung von Oligonukleotiden
JP2002524410A (ja) * 1998-09-08 2002-08-06 スミスクライン・ビーチャム・コーポレイション リプスタチン誘導体−可溶性繊維錠剤
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
AU2199500A (en) * 1998-12-23 2000-07-31 Alza Corporation Gastric retention dosage form having multiple layers
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
CA2259730A1 (en) * 1999-01-18 2000-07-18 Bernard Charles Sherman Sustained release tablets containing bupropion hydrochloride
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
PT1187601E (pt) * 1999-06-07 2005-11-30 Altana Pharma Ag Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
US7815590B2 (en) 1999-08-05 2010-10-19 Broncus Technologies, Inc. Devices for maintaining patency of surgically created channels in tissue
BR0007360A (pt) * 1999-12-23 2001-08-14 Johnson & Johnson Composição de liberação controlada
DE10085395T1 (de) * 1999-12-27 2002-12-05 Kimberly Clark Co Fasern, die eine kontrollierte Abgabe eines aktiven Mittels zur Verfügung stellen
IL150568A0 (en) * 2000-02-04 2003-02-12 Depomed Inc A controlled release oral drug dosage form
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
CZ20023003A3 (cs) 2000-03-30 2002-11-13 Bristol-Myers Squibb Company Perličky s trvalým uvolňováním obsahující stavudin
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US7056531B1 (en) * 2000-05-04 2006-06-06 Nature's Way Products, Inc. Sustained release compositions for orally administered substances and methods
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
AU2002258013A1 (en) * 2001-04-10 2002-10-28 Fakhreddin Jamali Animal model for evaluating analgesics
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
JP2004537401A (ja) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
IL160363A0 (en) * 2001-08-16 2004-07-25 Oregon State Expandable gastric retention device
US20030060483A1 (en) * 2001-09-24 2003-03-27 Day Charles E. Method of increasing pharmaceutical market
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20030147965A1 (en) * 2001-12-10 2003-08-07 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US7053029B2 (en) * 2002-03-27 2006-05-30 Kimberly-Clark Worldwide, Inc. Use indicating soap
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
EP1515701B1 (de) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Verfahren zur herstellung von mehrschichtigen tabletten die thiazolidinedione und biguanide enthalten
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
DE60316579T2 (de) * 2002-08-13 2008-07-03 Medtronic, Inc., Minneapolis System zur abgabe von wirkstoffen mit einem hydrophoben cellulose-derivat
AU2003258206A1 (en) * 2002-08-13 2004-02-25 Medtronic, Inc. Active agent delivery system including a polyurethane, medical device, and method
US20040086569A1 (en) * 2002-08-13 2004-05-06 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
EP1530489A1 (de) * 2002-08-13 2005-05-18 Medtronic, Inc. Arzneimittel-freigabesystem enthaltend ein hydrophiles polymergemisch
US20040047911A1 (en) * 2002-08-13 2004-03-11 Medtronic, Inc. Active agent delivery system including a poly(ethylene-co-(meth)Acrylate), medical device, and method
AU2003255874A1 (en) * 2002-08-16 2004-03-03 Orchid Health Care, A Division Of Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition of a cephalosporin antibiotic
US20040033262A1 (en) * 2002-08-19 2004-02-19 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
US7960326B2 (en) * 2002-09-05 2011-06-14 Kimberly-Clark Worldwide, Inc. Extruded cleansing product
JP2006510593A (ja) * 2002-09-12 2006-03-30 ザ ユニヴァーシティ オヴ シカゴ 胃内容排出及び胃不全麻痺のモニタリング及び診断
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US20040224017A1 (en) * 2003-03-14 2004-11-11 Nirmal Mulye Process for preparing sustained release tablets
US7375111B2 (en) 2003-04-29 2008-05-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2004103291A2 (en) * 2003-05-16 2004-12-02 Eisai Co., Ltd. Extended release compositions of proton pump inhibitor
EP1638529B1 (de) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Orale zusammensetzung mit verlängerter freisetzung
US7554452B2 (en) * 2003-07-18 2009-06-30 Cary Cole Ingestible tracking and locating device
US8002740B2 (en) 2003-07-18 2011-08-23 Broncus Technologies, Inc. Devices for maintaining patency of surgically created channels in tissue
US8308682B2 (en) 2003-07-18 2012-11-13 Broncus Medical Inc. Devices for maintaining patency of surgically created channels in tissue
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005007074A2 (en) * 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648407A4 (de) 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
ATE354354T1 (de) 2003-07-30 2007-03-15 Merrion Res I Ltd Verfahren und maschine für die automatische herstellung von magensaftresistenten kapseln
WO2005014906A2 (en) * 2003-08-07 2005-02-17 Polymer Group, Inc. Cleaning sheet with improved three-dimensional cleaning surface
ATE454138T1 (de) 2003-08-08 2010-01-15 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1684820A2 (de) * 2003-08-13 2006-08-02 Medtronic, Inc. Systeme zur abgabe von wirkstoffen mit einer mischbaren polymermischung, medizinprodukte und -verfahren
JP2008511339A (ja) * 2003-08-13 2008-04-17 メドトロニック・インコーポレーテッド 相溶性ポリマーブレンドの単層を含む活性薬剤送達システム、医療用デバイス、及び方法
EP1510208A1 (de) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
US20050053655A1 (en) * 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20060094782A9 (en) * 2003-10-31 2006-05-04 Wong Patrick S Compositions and dosage forms for enhanced absorption
US20080089933A1 (en) 2006-10-16 2008-04-17 Amir Alon Device and method for reducing calorie intake
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US8409167B2 (en) 2004-07-19 2013-04-02 Broncus Medical Inc Devices for delivering substances through an extra-anatomic opening created in an airway
US7669388B2 (en) * 2004-07-30 2010-03-02 Merrion Research Iii Limited Process and machine for automated manufacture of gastro-retentive devices
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US8691269B2 (en) * 2004-11-05 2014-04-08 Martin Pavlov Mintchev Controlled degradation of expandable polymers in gastric volume reduction treatment
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
KR100670798B1 (ko) * 2004-12-17 2007-01-17 한국전자통신연구원 데이터베이스 캐시 시스템
JP5117196B2 (ja) * 2005-01-04 2013-01-09 テイコク ファーマ ユーエスエー インコーポレーテッド 冷却局所用貼付製剤
US8852083B2 (en) * 2005-02-04 2014-10-07 Uti Limited Partnership Self-stabilized encapsulated imaging system
US7829000B2 (en) * 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
US20060257484A1 (en) * 2005-04-19 2006-11-16 Hwang Stephen S Combination of tramadol and substances that comprise gabapentin
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US7541347B2 (en) * 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
NZ561375A (en) * 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
EP1915990A1 (de) * 2005-07-15 2008-04-30 Kissei Pharmaceutical Co., Ltd. Präparat mit verzögerter freisetzung
EP1745775B1 (de) * 2005-07-19 2008-05-28 Ethypharm Gastroretentive Zusammensetzungen und Verfahren zur Herstellung
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
CN101534805A (zh) * 2005-10-24 2009-09-16 帝国制药美国公司 包含n，2，3-三甲基-2-异丙基丁酰胺的局部止痛组合物及其使用方法
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517394A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド ゾニサミドの徐放性製剤
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
RU2008142623A (ru) * 2006-03-28 2010-05-10 Джелесис, Инк. (Us) Способ и лекарственный препарат для повышения набухаемости гидрогеля и/или продолжительности его действия в желудке у животного организма, способ и лекарственный препарат для доставки лекарственного средства
EP2007351A2 (de) * 2006-03-30 2008-12-31 Gelesis, Inc. Polymermaterialien als magenfüller und ihre zubereitung
US9011930B2 (en) 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007275251A1 (en) * 2006-07-19 2008-01-24 Smithkline Beecham Corporation Method for radiolabeling formulations for gamma scintigraphy assessment
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
MX2009004871A (es) 2006-11-09 2009-06-16 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
EP2121107B1 (de) * 2006-12-18 2012-10-31 Eatlittle Inc. Vorrichtung zur abgabe einer substanz
ZA200904573B (en) 2006-12-22 2010-09-29 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
US20100112053A1 (en) 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
CA2682661C (en) 2007-03-22 2017-03-14 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
CA2694602A1 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8333754B2 (en) * 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
MX340249B (es) 2008-08-15 2016-07-01 Depomed Inc Composiciones farmacéuticas retentivas gástricas para tratamiento y prevención de transtornos del sistema nervioso central (cns).
AU2009301994B2 (en) * 2008-10-08 2016-10-20 Bioplus Life Sciences Pvt. Ltd. Sustained release drug delivery system
KR20110120866A (ko) 2009-01-12 2011-11-04 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
AR076341A1 (es) 2009-04-20 2011-06-01 Elcelyx Therapeutics Inc Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion
CN102711800A (zh) 2009-09-23 2012-10-03 拜奥基尔公司 治疗糖尿病的组合物和方法
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
EP3659604A1 (de) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
WO2011111068A2 (en) 2010-03-09 2011-09-15 Council Of Scientific And Industrial Research Gastroretentive, extended release composition of therapeutic agent
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
EP2575798B1 (de) * 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosierungszubereitung von gaba analoga
US20120045510A1 (en) * 2010-08-18 2012-02-23 Joel Waldman Tablet sleeve for improved performance
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA2815024A1 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2817229A1 (en) 2010-11-08 2012-05-18 Naihong Li Gels and hydrogels
AP3815A (en) 2010-12-22 2016-09-30 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
US10195114B2 (en) * 2012-11-19 2019-02-05 Guill Tool & Engineering Co., Inc Microlayer coextrusion to create a time-release drug substance delivery product
US20120177730A1 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
US8722066B2 (en) 2011-03-29 2014-05-13 Primigenia, LLC Devices and methods for weight control and weight loss
US8709034B2 (en) 2011-05-13 2014-04-29 Broncus Medical Inc. Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
WO2012158553A2 (en) 2011-05-13 2012-11-22 Broncus Technologies, Inc. Methods and devices for excision of tissue
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
WO2013078235A1 (en) 2011-11-23 2013-05-30 Broncus Medical Inc Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
PL3730132T3 (pl) 2012-06-06 2022-10-10 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
DK2858604T3 (da) 2012-06-07 2024-05-21 Epitomee Medical Ltd Ekspanderet anordning
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2932574C (en) 2013-12-05 2023-03-07 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CA2951884A1 (en) 2014-06-11 2015-12-17 Massachusetts Institute Of Technology Residence structures and related methods
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
JP2018511127A (ja) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 渇望入力及び支援システム
KR101897218B1 (ko) * 2015-05-11 2018-09-10 주식회사 아모라이프사이언스 수용성 고분자를 이용한 세포 배양 지지체
JP7085473B2 (ja) * 2015-10-23 2022-06-16 リンドラ セラピューティクス， インコーポレイティド 治療薬の持続放出用の胃内滞留システム及びその使用方法
CN120827528A (zh) 2015-12-08 2025-10-24 林德拉治疗公司 用于胃驻留系统的几何构型
SG10202005637RA (en) * 2015-12-22 2020-07-29 Mccormick & Co Inc High integrity encapsulation product
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
CA3025650A1 (en) 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CN117257753A (zh) 2017-05-17 2023-12-22 麻省理工学院 自扶正制品
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
EP3634382A4 (de) 2017-06-09 2021-07-07 Lyndra Therapeutics, Inc. Magenverweilsysteme mit freisetzungsratenmodulierenden filmen
US11793751B2 (en) * 2017-09-20 2023-10-24 Lyndra Therapeutics, Inc. Encapsulation of gastric residence systems
EP3717453A4 (de) 2017-12-01 2021-07-28 Ultragenyx Pharmaceutical Inc. Kreatin-prodrugs, zusammensetzungen und verfahren zur verwendung davon
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
EP3740188A1 (de) 2017-12-18 2020-11-25 Tris Pharma, Inc. Pharmazeutische zusammensetzungen mit einem schwimmenden interpenetrierenden polymernetzwerkbildungssystem
EP3740189A1 (de) 2017-12-18 2020-11-25 Tris Pharma, Inc. Arzneimittelpulverzusammensetzung mit modifizierter freisetzung mit gastro-retentiven raft-bildenden systemen mit triggerimpuls-arzneimittelfreisetzung
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
WO2019240740A1 (en) 2017-12-22 2019-12-19 Arasteh Ari Azhir Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US11202903B2 (en) 2018-05-17 2021-12-21 Massachusetts Institute Of Technology Systems for electrical stimulation
CN112118886B (zh) 2018-05-23 2022-08-23 上海汉都医药科技有限公司 活性药物成分的控释系统及其制备方法
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
CN114191307A (zh) 2020-09-17 2022-03-18 上海汉都医药科技有限公司 一种口腔滞留装置及其制备方法
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2021535090A (ja) * 2018-08-15 2021-12-16 リンドラ セラピューティクス， インコーポレイティド 治療薬物の腸内送達のためのシステム
WO2020102695A1 (en) 2018-11-16 2020-05-22 Cti (Assignment For Benefit Of Creditors) Llc Thermally regulated transdermal drug delivery system
JP2022523121A (ja) 2019-02-01 2022-04-21 マサチューセッツ インスティテュート オブ テクノロジー 液体注入のためのシステムおよび方法
EP3968980A1 (de) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Behandlung von nächtlichen symptomen und morgendlicher akinesie bei personen mit morbus parkinson
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
EP4221694A4 (de) * 2020-09-30 2024-10-16 Blaesi, Aron H. Gastroretentive strukturierte dosierungsform
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786813A (en) * 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
DK0418565T3 (da) * 1989-09-21 1995-01-23 American Cyanamid Co Pulserende system til afgivelse af minocyclin en gang dagligt
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands

Also Published As

Publication number Publication date
WO1999007342A1 (en) 1999-02-18
AU8699298A (en) 1999-03-01
EP1003476A1 (de) 2000-05-31
EP1003476B1 (de) 2004-12-22
US6120803A (en) 2000-09-19
DE69828289D1 (de) 2005-01-27
PT1003476E (pt) 2005-05-31
HK1028196A1 (en) 2001-02-09
DE69828289T2 (de) 2005-06-02
US6548083B1 (en) 2003-04-15
JP2001527023A (ja) 2001-12-25
ES2234139T3 (es) 2005-06-16

Similar Documents

Publication Publication Date Title
ATE285226T1 (de) Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs
ATE200421T1 (de) Mit bändern versehene dosisform zur verlängerten freisetzung eines wirkstoffs
IE781163L (en) Sustained release of veterinary medicaments
TNSN01123A1 (fr) Formes posologiques nouvelles a liberation controlee
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
DK0998916T3 (da) Lægemidler til administration til slimhinden
ES2052656T3 (es) Una formulacion de revestimiento para la encapsulacion de sustancias bioactivas.
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
MXPA99001958A (es) Tableta con liberacion controlada de clorhidrato de alfuzosina.
BE901994A (fr) Comprimes de principes actifs pharmaceutiques a delitement rapide, stables au stockage.
MXPA02012792A (es) Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos.
DE69710757D1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
AU4989997A (en) Soluble form osmotic dose delivery system
MX9701465A (es) Formulacion de acetaminofeno, de liberacion sostenida.
KR880002502A (ko) 산에 민감한 유익한 약제의 투여용 제형(劑形)
ES2189018T3 (es) Utilizacion de polvos de polimeros o granulados de polimeros redispersables para el revestimiento de formas de administracion farmaceuticas o agroquimicas.
DE60038536D1 (de) Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
KR950703923A (ko) 조절 방출 장치(controlled release device)
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
AR002049A1 (es) Una composicion farmaceutica para la administracion oral de agentes activos que tienen baja solubilidad en agua y el procedimiento para prepararla
SE9603480L (sv) Beredningsform för svårlösliga läkemedel
HK1039746A1 (zh) 用於口释放的液体药物
TH27939B (th) สูตรส่วนผสมทางเภสัช
IT1265224B1 (it) Composizioni farmaceutiche per uso orale per il trattamento delle manifestazioni ulcerose gastro-duodenali ed esofagee

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties